Glaxo - Another pharma major ( MNC this time ) which is in a major uptrend. This counter has also been a frequent feature in our editions ( click here to view previous editions ) and has been a profitable investment. The stock is perceived as a safe haven for investment and especially so during high volatility in the markets. This company will by and far be the biggest beneficiary of the EMR / IPR regime after 2005. A good buy for the patient investors.

Your call of action - 

• Investors / cash segment players - Delivery based buying is recommended at the 440 levels and positions should be held with a stop loss at the 420 levels. Expect 485 levels in a conducive market in a few weeks time.

• Aggressive F&O traders - N/a

• Derivatives contract size - N/a